JP2022024039A - Composition containing xanthophyll and processed product of trapa genus plant - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a novel composition containing xanthophyll, or a salt thereof, and a processed product of a Trapa genus plant, and a novel ophthalmic composition containing a processed product of a Trapa genus plant.

SOLUTION: This composition contains xanthophyll, or a salt thereof, and a processed product of a Trapa genus plant. Preferably, the xanthophyll is at least one selected from the group consisting of lutein, astaxanthin, β-cryptoxanthin, zeaxanthin, mesozeaxanthin, canthaxanthin, capsanthin and fucoxanthin.

SELECTED DRAWING: None

COPYRIGHT: (C)2022,JPO&INPIT

Description

The present invention is 1) a novel composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica, 2) a novel ophthalmic composition containing a processed product of Trapa japonica, and 3) lutein or a salt thereof. The present invention relates to a new use of an ophthalmic composition containing. The composition of the present invention can be used for prevention and / or improvement of visual function deterioration and the like and prevention and / or treatment of eye diseases and the like.

With the spread of personal computers, the Internet, smartphones, etc., an increasing number of people complain of eye fatigue (eye strain) and associated systemic fatigue (eye strain). In addition, deterioration of visual function associated with aging and eye diseases such as presbyopia, cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy is serious because it causes a significant decrease in quality of life (QOL). It has become a social problem. Therefore, the number of people who complain of troubles caused by the eyes or eyes (eye strain, aging of the eyes, various diseases caused by them) is increasing year by year, and the visual function is maintained to prevent troubles caused by the eyes or eyes. There is also an increasing need for supplements that improve or medicines that treat eye or eye problems.

In particular, presbyopia loses its elasticity due to aging of the crystalline lens (opacity (white turbidity), hardening, etc.) of the crystalline lens due to aging and extreme use of IT tools such as personal computers, the Internet, and smartphones for a long period of time. It is one of the typical troubles caused by eyes or eyes with subjective symptoms such as eyestrain, haze, and stiff shoulders due to impaired eye focus adjustment function.

Xanthophyll is a carotenoid-derived pigment, and compounds containing lutein, astaxanthin, zeaxanthin, mesozeaxanthin and the like are known. In addition, since these xanthophylls cannot be biosynthesized in the human body, humans need to ingest xanthophylls from food or the like. Further, xanthophyll is also known to improve accommodation dysfunction and eye strain of the eye (Patent Document 1).

Lutein is a type of carotenoid that is abundant in green and yellow vegetables, and is one of the major carotenoids in the body. Although lutein has an antioxidant effect, it is consumed by aging, ultraviolet rays, etc., so it is necessary to take it continuously through daily meals and supplements such as Santeltax (registered trademark) 20 (Non-Patent Document 1). Furthermore, it has been pointed out that lack of lutein in the body may cause various eye problems such as cataract, age-related macular degeneration, and dry eye.

Astaxanthin is a kind of carotenoid contained in salmon, salmon roe, crab, shrimp, red sea bream and the like. Astaxanthin is a pigment biosynthesized by Haematococcus algae, and this astaxanthin also has an antioxidant effect. In addition, astaxanthin is known to be useful for improving eye inflammatory diseases such as eyestrain and uveitis, and is incorporated into many supplements and cosmetics.

Zeaxanthin, like lutein, is a type of carotenoid, a fat-soluble substance similar to β-carotene, and a structural isomer of lutein. In addition, since zeaxanthin is abundant in the macula like lutein, it is said that zeaxanthin also has a function of protecting the macula like lutein.

Mesozeaxanthin is a metabolite of lutein and is a steric isomer of zeaxanthin. In addition, mesozeaxanthin is said to have the same function as zeaxanthin.

An extract of a trapa japonica plant obtained by hot-water extraction of the peel of a trapa japonica plant, particularly a trapa japonica extract, is called a trapa japonica extract and is known to have a saccharification inhibitory effect (Patent Document 2). Advanced glycation end products (AGEs) produced by glycation are also known to be involved in the development of various aging phenomena and diseases by causing denaturation and functional deterioration of biological proteins such as collagen and elastin. ing. By suppressing this glycation action, it is expected to prevent the aging of living organisms, especially the aging of the skin. Therefore, the Tobishi extract is blended in cosmetics and the like.

Ultraviolet rays are invisible electromagnetic waves having a wavelength of 10 to 400 nm, and those having a wavelength of less than 280 nm are called UV-C, those having a wavelength of 280 to 315 nm are called UV-B, and those having a wavelength of 315 to 400 nm are called UV-A. In addition, ultraviolet rays have useful effects such as sterilization and disinfection, synthesis of vitamin D in the body, blood circulation to the living body, and promotion of metabolism, but on the other hand, they induce skin cancer due to DNA damage, generate skin stains, and each tissue. It is also widely known that it causes accelerated aging and eye damage. It is also known that ultraviolet rays are radiated from IT tools such as personal computers, the Internet, and smartphones.

However, the use of xanthophile or a salt thereof in combination with a processed product of Trapa japonica, for example, a composition containing xanthophile or a salt thereof and a processed product of Trapa japonica, 1) a corneal membrane induced by ultraviolet irradiation, etc. It is not known to suppress the epithelial cell death of the trapa japonica, 2) to suppress the opacity (white turbidity) of the crystalline lens of the diabetic model rat, and 3) to suppress or ameliorate the damage to the retina of the diabetic model rat.

In addition, the use of a processed product of Trapa japonica alone, for example, a composition containing a processed product of Trapa japonica, 1) suppresses epithelial cell death such as the cornea induced by ultraviolet irradiation, and 2) It is also not known to suppress the opacity (white turbidity) of the crystalline lens of the diabetic model rat, and 3) to suppress or improve the damage to the retina of the diabetic model rat.

Furthermore, it is not known that lutein or a salt thereof is used alone, and that a composition containing lutein or a salt thereof suppresses epithelial cell death such as cornea induced by ultraviolet irradiation.

Japanese Patent Application Laid-Open No. 2008-297222 JP-A-2014-49464

Sawa M, Gomi F, Hara C, Nishida K. Effects of a lutein supplement on the plasma lutein concentration and macular pigment in patients with central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2014 Jul 29; 55 (8): 5238-44. doi: 10.1167 / iovs.14-14470.

The problems to be solved by the present invention are 1) a novel composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica and its ophthalmic use, and 2) a novel ophthalmic use containing a processed product of Trapa japonica. It is to provide a novel use of a composition, and 3) an ophthalmic composition containing lutein or a salt thereof.

The present inventors effectively suppress corneal epithelial cell death, suppress opacity of the crystalline lens, and retina by using a combination of lutein and hisashi extract, hisi extract alone, or lutein alone. It has been found to suppress or ameliorate damage. That is, a combination of xanthophyll or a salt thereof and a processed product of Trapa, a processed product of Trapa, or lutein or a salt thereof acts on the cornea, lens, retina, etc. constituting the eye to reduce visual function and the like. The present invention has been completed by finding the prevention, treatment or amelioration of the accompanying subjective symptoms.

That is, the present invention relates to the following.
Item 1-1. A composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-2. Item 12. The composition according to Item 1-1, wherein the xanthophyll is at least one selected from the group consisting of lutein, astaxanthin, β-cryptoxanthin, zeaxanthin, mesozeaxanthin, canthaxanthin, capsanthin and fucoxanthin.
Item 1-3. Item 2. The composition according to Item 1-1 or 1-2, wherein the xanthophyll is at least one selected from the group consisting of lutein, astaxanthin, zeaxanthin and mesozeaxanthin.
Item 1-4. Any one of Items 1-1 to 1-3, wherein the processed product of Trapa japonica is a processed product of at least one Trapa plant selected from the group consisting of Trapa incisa, Trapa incisa, Trapa japonica, Trapa japonica, and Water chestnut. The composition according to one item.
Item 1-5. Item 6. The composition according to any one of Items 1-1 to 1-4, wherein the processed product of Trapa japonica is a pulverized product or an extract of the pericarp of Trapa japonica.
Item 1-6. Item 2. The composition according to any one of Items 1-1 to 1-5, wherein the processed product of the genus Trapa contains 0.1 to 80% by weight of polyphenol based on the total weight of the processed product of Trapa japonica. ..
Item 1-7. A composition containing lutein or a salt thereof and a processed product of Tobishi.
Item 1-8. Item 2. The composition according to Item 1-7, wherein the processed product of Tobishi is a pulverized product and / or an extract of pericarp of Tobishi.
Item 1-9. Item 2. The composition according to Item 1-7 or 1-8, wherein the processed Tobishi product contains 0.1 to 80% by weight of polyphenol based on the total weight of the processed Tobishi product.
Item 1-10. Item 6. The composition according to any one of Items 1-1 to 1-9, wherein the composition is for oral or parenteral use.
Item 1-11. Item 6. The composition according to any one of Items 1-1 to 1-10, wherein the composition is for food or drink or pharmaceutical use.
Item 1-12. Item 6. The composition according to any one of Items 1-1 to 1-11, wherein the composition is for a supplement.
Item 1-13. Item 6. The composition according to any one of Items 1-1 to 1-12, wherein the composition is for ophthalmology.
Item 1-14. Item 6. The composition according to any one of Items 1-1 to 1-13, wherein the composition is a soft capsule, a hard capsule, a liquid preparation, a jelly, a gummy candy, a tablet or a powder.
Item 1-15. Item 8. The composition according to any one of Items 1-1 to 1-14, for preventing and / or ameliorating visual function deterioration and associated subjective symptoms.
Item 1-16. Item 2. The composition according to Item 1-15, wherein the deterioration of visual function is eye fatigue, aging of the eye, or deterioration of the accommodation function of the eye.
Item 1-17. Item 2. The composition according to Item 1-15 or 1-16, wherein the visual dysfunction is a visual dysfunction induced by aging, ultraviolet rays, poor blood circulation, dryness, active oxygen and / or inflammation.
Item 1-18. Item 5. The composition according to Item 1-15, wherein the subjective symptom is stiff shoulders, nape, back or lower back.
Item 1-19. Items 1-1 to 1-14 for the prevention and / or treatment of eye diseases.
Item 1-20. Item 12. The composition according to Item 1-19, wherein the eye disease is an eye disease induced by aging, ultraviolet rays, poor circulation, dryness, active oxygen and / or inflammation.
Item 1-21. Eye diseases include eye fatigue, cataracts, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, central serous chorioretinopathy, glaucoma, vasculitis, presbyopia, myopia, dry eyes, winglets and inflammatory Item 2. The composition according to Item 1-19 or 1-20, which is selected from the group consisting of eye diseases.
Item 1-22. Item 6. The composition according to any one of Items 1-1 to 1-14, for preventing, ameliorating and / or treating corneal disorders.
Item 1-23. Item 2. The composition according to Item 1-22, wherein the corneal disorder is an ultraviolet-induced corneal disorder.
Item 1-24. Item 6. The composition according to any one of Items 1-1 to 1-14, for preventing, ameliorating and / or treating lens degeneration.
Item 1-25. Item 2. The composition according to Item 1-24, wherein the lens degeneration is opacity or hardening of the lens.
Item 1-26. Item 6. The composition according to any one of Items 1-1 to 1-14, for preventing, ameliorating and / or treating a decrease in accommodation function.
Item 1-27. Item 2. The composition according to Item 1-26, wherein the accommodation function is an accommodation function.
Item 1-28. Item 6. The composition according to any one of Items 1-1 to 1-14, for preventing, ameliorating and / or treating retinochoroidal disorders.
Item 1-29. Item 2. The composition according to Item 1-28, wherein the retinal choroidal disorder is a damage to the retina.
Item 1-30. An agent for preventing and / or ameliorating visual dysfunction and associated subjective symptoms, which is characterized by combining xanthophyll or a salt thereof with a processed product of the genus Trapa.
Item 1-31. A prophylactic and / or therapeutic agent for eye diseases, which comprises a combination of xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-32. A preventive, ameliorating and / or therapeutic agent for corneal disorders, which comprises combining xanthophyll or a salt thereof with a processed product of the genus Trapa.
Item 1-33. Item 3. The composition according to Item 1-32, wherein the corneal disorder is UV-induced corneal damage.
Item 1-34. A prophylactic, ameliorating and / or therapeutic agent for lens degeneration characterized by a combination of xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-35. Item 6. The prophylactic, ameliorating and / or therapeutic agent according to Item 1-34, wherein the lens degeneration is lens opacity or hardening.
Item 1-36. A preventive, ameliorating and / or therapeutic agent for the deterioration of accommodation function, which is characterized by combining xanthophyll or a salt thereof with a processed product of the genus Trapa.
Item 1-37. Item 6. The prophylactic, ameliorating and / or therapeutic agent according to Item 1-36, wherein the accommodation function is an accommodation function.
Item 1-38. A prophylactic, ameliorating and / or therapeutic agent for retinal disorders characterized by a combination of xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-39. The prophylactic, ameliorating and / or therapeutic agent according to Item 1-38, wherein the retinal choroidal disorder is retinal damage.
The invention in which items 1-1 to 1-39 are appropriately selected and combined is also within the scope of the present invention.

The present invention also relates to the following.
Item 1-40. Use of a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica for the prevention and / or improvement of visual dysfunction and associated subjective symptoms.
Item 1-41. A method for preventing, ameliorating and / or treating a decrease in visual function and associated subjective symptoms, which comprises administering an effective amount of xanthophyll or a salt thereof and a processed product of Trapa japonica.
Item 1-42. Use of a composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa, for the prevention and / or treatment of eye diseases.
Item 1-43. A method of preventing, ameliorating and / or treating an eye disease, comprising administering an effective amount of xanthophyll or a salt thereof and a processed product of Trapa japonica.
Item 1-44. A Maillard reaction inhibitor containing xanthophyll or a salt thereof and a processed product of Trapa japonica.
Item 1-45. An antioxidant containing xanthophylls or salts thereof and processed products of Trapa japonica.
Item 1-46. An active oxygen scavenger containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-47. A phototoxicity inhibitor containing xanthophyll or a salt thereof and a processed product of Trapa japonica.
Item 1-48. Item 2. The phototoxicity inhibitor according to Item 1-47, wherein the light is ultraviolet light.
Item 1-49. An epithelial cell death inhibitor containing xanthophyll or a salt thereof and a processed product of Trapa japonica.
Item 1-50. Item 6. The epithelial cell death inhibitor according to Item 1-49, wherein the epithelial cell is a corneal epithelial cell.
Item 1-51. A lens denaturation inhibitor containing xanthophyll or a salt thereof and a processed product of Trapa japonica.
Item 1-52. Item 5. The lens degeneration inhibitor according to Item 1-51, wherein the lens degeneration is opacity or hardening of the lens.
Item 1-53. An anti-aging agent containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-54. An anti-inflammatory agent containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-55. An agent for suppressing damage to the reticulochoroid containing xanthophyll or a salt thereof and a processed product of the genus Trapa.
Item 1-56. Item 2. The agent for suppressing damage to the retinal choroid according to Item 1-55, wherein the retinal choroid is the retina.
Item 1-57. A composition containing xanthophylls or salts thereof and processed products of Trapa japonica for use in the prevention or amelioration of eye symptoms and / or findings.
Item 1-58. Use of compositions containing xanthophylls or salts thereof and processed Trapa japonica in the manufacture of foods and drinks or pharmaceuticals for the prevention or amelioration of eye symptoms and / or findings.
Item 1-59. Use in the prevention or amelioration of ocular symptoms and / or findings of compositions containing xanthophylls or salts thereof and processed Trapa japonica.
Item 1-60. A method for use in the prevention or amelioration of eye symptoms and / or findings, comprising administering an effective amount of a composition containing xanthophyll or a salt thereof and a processed Trapa japonica.
Item 1-61. Combination of xanthophylls or salts thereof and Trapa japonica processed products (combination of mixture composition or single agent composition) for use in the prevention or amelioration of eye symptoms and / or findings.
Item 1-62. A combination of xanthophylls or salts thereof and processed Trapa japonica (combination of mixture composition or single agent composition) for use in the prevention and / or treatment of eye diseases.
Item 1-63. Combination of xanthophylls or salts thereof and Trapa japonica processed products (combination of mixture composition or single agent composition) in the manufacture of foods and drinks or pharmaceuticals for the prevention or improvement of eye symptoms and / or findings. use.
Item 1-64. Use of xanthophylls or salts thereof and combinations of Trapa japonica processed products (combination of mixture composition or single agent composition) in the manufacture of foods and drinks or pharmaceuticals for the prevention and / or treatment of eye diseases.
Item 1-65. Use of xanthophylls or salts thereof and a combination of Trapa japonica processed products (combination of combination composition or single agent composition) for the prevention or amelioration of eye symptoms and / or findings.
Item 1-66. Use of xanthophylls or salts thereof and a combination of Trapa japonica processed products (combination of mixture composition or single agent composition) in the prevention and / or treatment of eye diseases.
Item 1-67. Use in the prevention or amelioration of ocular symptoms and / or findings, including administration of effective amounts of xanthophylls or salts thereof and a combination of Trapa japonica processed products (combination of mixture composition or single agent composition). The way for.
Item 1-68. For use in the prevention and / or treatment of eye diseases, including the administration of effective amounts of xanthophylls or salts thereof and a combination of Trapa japonica processed products (combination of mixture composition or single agent composition). Method.
The invention in which items 1-1 to 1-68 are appropriately selected and combined is also within the scope of the present invention.

Further, another aspect of the present invention relates to the following.
Item 2-1. An ophthalmic composition containing a processed product of the genus Trapa.
Item 2-2. Item 2. The ophthalmic composition according to Item 2-1. The processed product of Trapa japonica is a processed product of at least one Trapa japonica plant selected from the group consisting of Trapa japonica, Trapa japonica, Trapa japonica, Trapa natans and Trapa natans.
Item 2-3. Item 2. The ophthalmic composition according to any one of Items 2-1 or 2-2, wherein the processed product of Trapa japonica is a pulverized product or an extract of the pericarp of Trapa japonica.
Item 2-4. Item 2. Ophthalmology according to any one of Items 2-1 to 2-3, wherein the processed product of the genus Trapa contains 0.1 to 80% by weight of polyphenol based on the total weight of the processed product of Trapa japonica. Composition.
Item 2-5. An ophthalmic composition containing a processed Tobishi product.
Item 2-6. Item 2. The ophthalmic composition according to Item 2-5, wherein the processed product of Tobishi is a pulverized product and / or an extract of pericarp of Tobishi.
Item 2-7. Item 2. The ophthalmic composition according to Item 2-5 or 2-6, wherein the processed product of Tobishi contains 0.1 to 80% by weight of polyphenol with respect to the total weight of the processed product of Tobishi.
Item 2-8. Item 2. The ophthalmic composition according to any one of Items 2-1 to 2-7, wherein the ophthalmic composition is oral or parenteral.
Item 2-9. Item 2. The ophthalmic composition according to any one of Items 2-1 to 2-8, wherein the ophthalmic composition is for food and drink or pharmaceutical use.
Item 2-10. Item 2. The ophthalmic composition according to any one of Items 2-1 to 2-9, wherein the ophthalmic composition is for a supplement.
Item 2-11. Item 2. The ophthalmic composition according to any one of Items 2-1 to 2-10, wherein the ophthalmic composition is a soft capsule, a hard capsule, a liquid preparation, a jelly, a gummy candy, a tablet or a powder.
Item 2-12. Item 8. The ophthalmic composition according to any one of Items 2-1 to 2-11, for preventing and / or ameliorating visual function deterioration and associated subjective symptoms.
Item 2-13. Item 2. The composition according to Item 1-12, wherein the deterioration of visual function is eye fatigue, aging of the eye, or deterioration of the accommodation function of the eye.
Item 2-14. Item 2. The composition according to Item 2-12 or 2-13, wherein the decrease in visual function is a decrease in visual function induced by aging, ultraviolet rays, poor blood circulation, dryness, active oxygen and / or inflammation.
Item 2-15. Item 2. The composition according to Item 2-12, wherein the subjective symptom is stiff shoulders, nape, back or lower back.
Item 2-16. Item 2. The ophthalmic composition according to Item 2-1 to Item 2-11 for prevention and / or treatment of eye diseases.
Item 2-17. Item 2. The ophthalmic composition according to Item 2-16, wherein the eye disease is induced by aging, ultraviolet rays, poor circulation, dryness, active oxygen and / or inflammation.
Item 2-18. Eye diseases include eye fatigue, cataracts, age-related macular degeneration, diabetic retinitis, retinitis pigmentosa, central serous chorioretinosis, glaucoma, vasculitis, presbyopia, myopia, dry eyes, winglets and inflammation. Item 2. The ophthalmic composition according to Item 2-16 or 2-17, which is selected from the group consisting of sexual eye diseases.
Item 2-19. Item 6. The ophthalmic composition according to any one of Items 2-1 to 2-11, for preventing, ameliorating and / or treating corneal disorders.
Item 2-20. Item 2. The ophthalmic composition according to Item 2-19, wherein the corneal disorder is an ultraviolet-induced corneal disorder.
Item 2-21. Item 6. The ophthalmic composition according to any one of Items 2-1 to 1-11, for preventing, ameliorating and / or treating lens degeneration.
Item 2-22. Item 2. The ophthalmic composition according to Item 2-21, wherein the lens degeneration is opacity or hardening of the lens.
Item 2-23. Item 6. The ophthalmic composition according to any one of Items 2-1 to 2-11, for preventing, ameliorating and / or treating deterioration of accommodation function.
Item 2-24. Item 2. The ophthalmic composition according to Item 2-23, wherein the accommodation function is an accommodation function.
Item 2-25. Item 6. The ophthalmic composition according to any one of Items 2-1 to 2-11, for preventing, ameliorating and / or treating retinochoroidal disorders.
Item 2-26. Item 2. The ophthalmic composition according to Item 2-25, wherein the retinal choroidal disorder is damage to the retina.
Item 2-27. An agent for preventing and / or improving visual function deterioration and associated subjective symptoms, which comprises a processed product of Trapa japonica.
Item 2-28. A preventive and / or therapeutic agent for eye diseases containing a processed product of the genus Trapa.
Item 2-29. A preventive, ameliorating and / or therapeutic agent for corneal disorders containing a processed product of the genus Trapa.
Item 2-30. Item 2. The prophylactic, ameliorating and / or therapeutic agent according to Item 2-29, wherein the corneal disorder is an ultraviolet-induced corneal disorder.
Item 2-31. A prophylactic, ameliorating and / or therapeutic agent for lens degeneration containing a processed product of the genus Trapa.
Item 2-32. Item 2. The prophylactic, ameliorating and / or therapeutic agent according to Item 2-31, wherein the lens degeneration is lens opacity or hardening.
Item 2-33. A prophylactic, ameliorating and / or therapeutic agent for deterioration of accommodation function containing a processed product of Trapa japonica.
Item 2-34. Item 2. The prophylactic, ameliorating and / or therapeutic agent according to Item 2-33, wherein the accommodation function is an accommodation function.
Item 2-35. A prophylactic, ameliorating and / or therapeutic agent for reticulochoroidal disorders containing a processed product of the genus Trapa.
Item 2-36. The prophylactic, ameliorating and / or therapeutic agent according to Item 2-35, wherein the retinal choroidal disorder is retinal damage.
The invention in which items 2-1 to 2-36 are appropriately selected and combined is also within the scope of the present invention.

The present invention also relates to the following.
Item 2-37. An ophthalmic composition containing a processed product of the genus Trapa, the use of the composition for the prevention and / or improvement of visual dysfunction and associated subjective symptoms.
Item 2-38. A method for preventing, ameliorating and / or treating a decrease in visual function and associated subjective symptoms, which comprises administering an effective amount of a processed product of the genus Trapa.
Item 2-39. An ophthalmic composition containing a processed product of the genus Trapa, the use of the composition for the prevention and / or treatment of eye diseases.
Item 2-40. A method of preventing, ameliorating and / or treating an eye disease, which comprises administering an effective amount of a processed product of Trapa japonica.
Item 2-41. A mailerd reaction inhibitor in the eye containing a processed product of the genus Hishi.
Item 2-42. Antioxidant in the eye containing a processed product of the genus Trapa.
Item 2-43. An active oxygen scavenger in the eye containing a processed product of the genus Trapa.
Item 2-44. A phototoxicity inhibitor in the eye containing a processed product of the genus Trapa.
Item 2-45. Item 2. The phototoxicity inhibitor according to Item 2-44, wherein the light is ultraviolet light.
Item 2-46. An epithelial cell death inhibitor containing a processed product of the genus Trapa.
Item 2-47. Item 2. The epithelial cell death inhibitor according to Item 2-46, wherein the epithelial cells are corneal epithelial cells.
Item 2-48. An inhibitor of lens denaturation containing a processed product of the genus Trapa.
Item 2-49. Item 2. The epithelial cell death inhibitor according to Item 2-48, wherein the lens degeneration is lens opacity or hardening.
Item 2-50. An anti-aging agent in the eye containing a processed product of the genus Trapa.
Item 2-51. An eye inflammation improving agent containing a processed product of the genus Trapa.
Item 2-52. An agent for suppressing damage to the reticulochoroid containing a processed product of the genus Trapa.
Item 2-53. Item 2. The agent for suppressing damage to the retinal choroid according to Item 2-52, wherein the retinal choroid is the retina.
Item 2-54. A processed product of the genus Trapa for use in the prevention or amelioration of eye symptoms and / or findings.
Item 2-55. Use of Trapa japonica processed products in the manufacture of foods and drinks or pharmaceuticals for the prevention or amelioration of eye symptoms and / or findings.
Item 2-56. Use in the prevention or amelioration of eye symptoms and / or findings of Trapa japonica processed products.
Item 2-57. A method for use in the prevention or amelioration of eye symptoms and / or findings, including administration of an effective amount of a processed Trapa plant.
The invention in which items 2-1 to 2-57 are appropriately selected and combined is also within the scope of the present invention.

Furthermore, another aspect of the present invention relates to the following.
Item 3-1. A corneal epithelial cell death inhibitor containing lutein or a salt thereof.
Item 3-2. Item 3. The corneal epithelial cell death inhibitor according to Item 3-1 which is corneal epithelial cell death induced by ultraviolet rays.
Item 3-3. Item 3. The corneal epithelial cell death inhibitor according to Item 3-1 or 3-2, wherein the ultraviolet rays are UV-B.
Item 3-4. An ophthalmic composition containing lutein or a salt thereof, for preventing and / or ameliorating UV-induced visual dysfunction and associated subjective symptoms.
Item 3-5. An ophthalmic composition containing lutein or a salt thereof for the prevention and / or treatment of ultraviolet-induced eye diseases.
Item 3-6. An ophthalmic composition containing lutein or a salt thereof for the prevention and / or treatment of ultraviolet-induced corneal disorders.
Item 3-7. Item 3. The ophthalmic composition according to Item 3-4 to 3-6, wherein the ophthalmic composition is oral or parenteral.
Item 3-8. Item 3. The ophthalmic composition according to Item 3-4 to 3-7, wherein the ophthalmic composition is for food or drink or pharmaceutical use.
Item 3-9. Item 6. The ophthalmic composition according to any one of Items 3-4 to 3-8, wherein the ophthalmic composition is for a supplement.
Item 3-10. Item 6. The ophthalmic composition according to any one of Items 3-4 to 3-9, wherein the ophthalmic composition is a soft capsule, a hard capsule, a liquid preparation, a jelly, a gummy candy, a tablet or a powder.
Item 3-11. Item 3. The ophthalmic composition according to Item 3-4, wherein the deterioration of visual function is eye fatigue, aging of the eye, or deterioration of the accommodation function of the eye.
Item 3-12. Item 3. The ophthalmic composition according to Item 3-4, wherein the subjective symptom is stiff shoulder, nape, back or lower back.
Item 3-13. Item 6. The ophthalmic composition according to Item 3-5, for the prevention and / or treatment of eye diseases.
Item 3-14. Item 3. Ophthalmology according to Item 3-5, wherein the eye disease is selected from the group consisting of eye strain, cataract, age-related yellow spot degeneration, vegetation inflammation, presbyopia, myopia, dry eye, pterygium and inflammatory eye disease. Composition for.
Item 3-15. Item 3. The ophthalmic composition according to Item 3-6, wherein the corneal disorder is a corneal epithelial cell disorder.
The invention in which items 3-1 to 3-15 are appropriately selected and combined is also within the scope of the present invention.

Item 3-16. Use of an ophthalmic composition containing lutein or a salt thereof for the prevention and / or amelioration of UV-induced visual dysfunction and associated subjective symptoms.
Item 3-17. A method for preventing and / or ameliorating UV-induced visual dysfunction and associated subjective symptoms, comprising administering an effective amount of lutein or a salt thereof.
Item 3-18. Use of an ophthalmic composition containing lutein or a salt thereof for the prevention and / or treatment of UV-induced eye diseases.
Item 3-19. A method of preventing and / or ameliorating UV-induced eye disease, comprising administering an effective amount of lutein or a salt thereof.
The invention in which items 3-1 to 3-19 are appropriately selected and combined is also within the scope of the present invention.

The present invention provides a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica. In addition, ophthalmic uses (prevention or amelioration of symptoms and / or findings related to the eye, prevention and / or treatment of eye diseases, etc.) of compositions containing xanthophile or its salts and processed products of Trapa plants, especially deterioration of visual function. To provide preventive and / or amelioration of such as, and preventive and / or therapeutic use of eye diseases and the like.

Compositions containing xanthophile or its salts and processed products of the genus Hishi effectively suppress UV irradiation-induced corneal epithelial cell death, resulting in UV-induced (due to DNA damage) vision. Prevention and / or improvement of functional deterioration (eye fatigue, eye aging, etc.) and associated subjective symptoms (stiffness of shoulders, neck muscles, back, hips, etc.) and eye diseases (eye fatigue, cataracts, age-related pterygium degeneration, inflammation, etc.) It is expected to be useful for the prevention and / or treatment of sexual eye diseases, pterygium, etc.).
At the same time, since it effectively suppresses the death of living cells caused by ultraviolet rays, it is also useful for prevention, improvement and / or treatment of induction of skin cancer, formation of skin stains, acceleration of aging of each tissue, etc. It is also expected.

In addition, since the composition containing xanthophile or a salt thereof and a processed product of the genus Hishi effectively suppresses the cloudiness of the crystalline lens, the cloudiness (whitening) of the crystalline lens, that is, the deterioration of visual function due to the degeneration of the crystalline lens is deteriorated. Prevention and / or improvement of (eye fatigue, presbyopia, deterioration of eye focus adjustment function, etc.) and associated subjective symptoms (stiffness of shoulders, neck muscles, back, hips, etc.) and eye diseases (eye fatigue, cataracts, etc.) It is expected to be useful for the prevention and / or treatment of presbyopia, etc.). In particular, degeneration of the crystalline lens greatly affects the focus adjustment function of the eye, and is therefore expected to be particularly effective in the prevention, improvement and / or treatment of presbyopia, myopia and the like, which are diseases related to the focus adjustment function.

In addition, compositions containing xanthophile or salts thereof and processed products of the genus Hishi effectively suppress or ameliorate damage to the retina, thus resulting in diminished visual function (eye fatigue, eye fatigue) associated with retinal choroid damage. Prevention and / or improvement of aging) and associated subjective symptoms (stiffness of shoulders, neck muscles, back, hips, etc.) and eye diseases (eye fatigue, age-related yellow spot degeneration, diabetic retinopathy, retinal pigment degeneration, central choroid) It is expected to be effective in the prevention and / or treatment of retinal choroidal diseases (retinal choroidal diseases such as retinal choroid disease, glaucoma, and vegetative inflammation).

The present invention provides an ophthalmic composition containing a processed product of a plant belonging to the genus Hishi. Further, the processed products of Trapa japonica are provided for ophthalmic use, particularly for prevention and / or improvement of visual function deterioration and prevention and / or treatment of eye diseases and the like.

The composition containing the processed product of the genus Hishi effectively suppresses the corneal epithelial cell death induced by ultraviolet irradiation, so that the visual function deterioration (eye strain, eye aging, etc.) caused by ultraviolet rays and the eye aging, etc. Prevention and / or improvement of subjective symptoms (stiffness of shoulders, neck muscles, back, hips, etc.) and prevention and / or improvement of eye diseases (eye strain, cataracts, age-related yellow spot degeneration, inflammatory eye diseases, pterygium, etc.) Expected to be useful for treatment.

In addition, since the composition containing the processed product of the genus Hishi effectively suppresses the white turbidity of the crystalline lens, the opacity of the crystalline lens (white turbidity), that is, the deterioration of visual function due to the degeneration of the crystalline lens (eye fatigue, Prevention and / or improvement of eye aging, deterioration of eye focus adjustment function, etc.) and associated subjective symptoms (stiffness of shoulders, neck muscles, back, waist, etc.) and eye diseases (eye fatigue, cataracts, presbyopia, etc.) Expected to be useful for prevention and / or treatment. In particular, degeneration of the crystalline lens greatly affects the focus adjustment function of the eye, and is therefore expected to be particularly effective in the prevention, improvement and / or treatment of presbyopia, myopia and the like, which are diseases related to the focus adjustment function.

In addition, compositions containing processed products of the genus Hishi effectively suppress or ameliorate damage to the retina, resulting in diminished visual function (eye fatigue, eye aging, etc.) associated with glaucoma damage and the like. Prevention and / or improvement of associated subjective symptoms (stiffness of shoulders, neck muscles, back, hips, etc.) and eye diseases (eye fatigue, age-related uveitis, diabetic retinopathy, retinal pigment degeneration, central serous chorioretinosis, It is expected to be effective in the prevention and / or treatment of reticchoroidal diseases such as glaucoma and uveitis.

The present invention provides a corneal epithelial cell death inhibitor containing lutein or a salt thereof. In particular, it provides an agent for suppressing UV-induced corneal epithelial cell death.

It is a graph which shows the cell viability of the corneal epithelial cell when the corneal epithelial cell was treated with lutein, Hishi extract before UV-B irradiation (120 mJ / cm ² ) (pharmaceutical test 1-1). It is a graph which shows the effect on the opacity (white turbidity) of the crystalline lens when treated with lutein and hissi extract (pharmacological test 2). 6 is a graph showing the effect on retinal damage when treated with lutein and hissi extract (pharmacological test 3). It is a graph which shows the cell viability of the corneal epithelial cell when the corneal epithelial cell was treated with astaxanthin, Hishi extract before UV-B irradiation (120 mJ / cm2) (pharmaceutical test 1-2). It is a photograph of the crystalline lens of a normal rat, and the numerical value on the upper right indicates the blood glucose level (pharmacological test 2). Complete cloudiness rate: (0/16) x 100 = 0% (complete cloudiness is a state in which the line under the crystalline lens cannot be seen). It is a photograph of the crystalline lens of a diabetic model rat treated with water for injection (base), and the numerical value on the upper right of the photograph indicates the blood glucose level (pharmaceutical test 2). Complete cloudiness rate: (12/16) x 100 = 75% (complete cloudiness is a state in which the line under the crystalline lens cannot be seen). It is a photograph of the crystalline lens of a diabetic model rat treated with Hishi extract (2 mg / kg), and the numerical value on the upper right of the photograph indicates the blood glucose level (pharmacological test 2). Complete cloudiness rate: (6/12) x 100 = 50% (complete cloudiness is a state in which the line under the crystalline lens cannot be seen). It is a photograph of the crystalline lens of a diabetic model rat treated with lutein (2 mL / kg), and the numerical value on the upper right of the photograph indicates the blood glucose level (pharmaceutical test 2). Complete cloudiness rate: (8/16) x 100 = 50% (complete cloudiness is a state in which the line under the crystalline lens cannot be seen). It is a photograph of the crystalline lens of a diabetic model rat treated with lutein (2 mL / kg) and Hishi extract (2 mg / kg), and the numerical value in the upper right of the photograph indicates the blood glucose level (pharmaceutical test 2). Complete cloudiness rate: (3/12) x 100 = 25% (complete cloudiness is a state in which the line under the crystalline lens cannot be seen).

Hereinafter, the present invention will be described in detail.

One aspect of the present invention is a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica.

In the present invention, xanthophyll is not particularly limited. Specific examples of xanthophylls include lutein, astaxanthin, zeaxanthin, mesozeaxanthin, β-cryptoxanthin, tunaxanthin, salmoxanthin, parasiloxanetin, violaxanthin, antheraxanthin, kukurubitaxanthin, diatoxanthin, alloxanthin, pectenol, pectenolone. , Mactraxanthin, capsanthin, capsanthinol, fucoxanthin, fucoxanthinol, peridinin, halosynthiaxanthin, astaxanthin, canthaxanthin, ekinenone, rhodoxanthin, bixin, norbicin and the like. Preferred examples include lutein, astaxanthin, β-cryptoxanthin, zeaxanthin, mesozeaxanthin, cantaxanthin, capsanthin or fucoxanthin, and particularly preferably lutein, astaxanthin, zeaxanthin or mesozeaxanthin. The xanthophyll is derived from natural substances such as plants, animals, and microorganisms (for example, plants such as marigold, spinach, and kale, animal fat, egg yolk, macula, crustacean shell, and crustacean shell). It may be obtained from the body surface of a crustacean, the red part of the muscle of a crustacean, the retina of the eye, the macula, etc.), or it may be chemically synthesized (manufactured by a general synthetic method). ) May be. Further, those derived from natural products are not particularly limited depending on the type of raw material, production area, production method and the like.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, lutein is a (3R, 3'R, 6'R) -β, ε-carotene-3,3'-diol:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, astaxanthin is (3S, 3'S) -3,3'-dihydroxy-β, β-carotene-4,4'-dione:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, β-cryptoxanthin is (3R) -β, β-carotene-3-ol:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, zeaxanthin is a (3R, 3'R) -β, β-carotene-3,3'-diol:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, mesozeaxanthin is a (3R, 3'S) -β, β-carotene-3,3'-diol:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, canthaxanthin is β, β-carotene-4,4'-dione:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, capsanthin is (3R, 3'S) -3,3'-dihydroxy-β, κ-carotene-6'-on:

And include its stereoisomers and their monoesters and / or diesters.

であり、その立体異性体、並びにそれらのモノエステル体及び／又はジエステル体を含む。 In the present invention, fucoxanthin is (3S, 3'S, 5R, 5'R, 6S, 6'R) -3'-acetoxy-6', 7'-didehydro-5,6-epoxy-5,5. ′, 6,6 ′, 7,8-hexahydro-3,5 ′-dihydroxy-8-oxo-β, β-carotene:

And include its stereoisomers and their monoesters and / or diesters.

In the present invention, xanthophylls include xanthophylls and / or stereoisomers thereof unless otherwise specified. Further, in the present invention, xanthophyll includes xanthophyll and / or an ester thereof unless otherwise specified. Further, xanthophyll esters include monoesters and / or diesters.

In the present invention, examples of the monoester form of xanthophile include esters esterified with lower or higher saturated fatty acids or lower or higher unsaturated fatty acids. Specific examples of the lower or higher saturated fatty acid or the lower or higher unsaturated fatty acid include acetic acid, lauric acid, myristic acid, capric acid, pentadecanoic acid, palmitic acid, palmitooleic acid, hebutadecanoic acid, ellaidic acid and lysinol. Acids, betroceric acid, baxenoic acid, eleosteaic acid, punicic acid, licanoic acid, parinalic acid, gadoric acid, 5-eicosenoic acid, 5-docosenic acid, cetolic acid, erucic acid, 5,13-docosadienoic acid, seracol acid , Decenoic acid, sterling acid, dodecenoic acid, oleic acid, stearate, eikosaopentaenoic acid, docosahexaenoic acid, linoleic acid, linolenic acid, arachidonic acid and the like.

In the present invention, as further monoesters of xanthophile, for example, amino acids such as glycine and alanine; monovalent or polyvalent carboxylic acids such as acetic acid and citric acid; inorganic acids such as phosphoric acid and sulfuric acid; sugars such as glucoside. Examples thereof include sugar fatty acids such as glycerosaccharide fatty acids and spingosaccharide fatty acids; fatty acids such as glycero fatty acids; monoesters esterified with glycerophosphate and the like. When a salt can be assumed as the monoester, the salt of the monoester is also included. Here, examples of the fatty acid derivative include a phospholipid type, an alcohol type, an ether type, a sucrose ester type, and a polyglycerin ester type of the fatty acid.

In the present invention, the diester form of xanthophile includes, for example, the lower saturated fatty acid, higher saturated fatty acid, lower unsaturated fatty acid, higher unsaturated fatty acid, amino acid, monovalent or polyvalent carboxylic acid, inorganic acid, sugar, sugar fatty acid, fatty acid. And diesters esterified with the same or different acids selected from the group consisting of glycerophosphate. When a salt can be assumed as the diester, the salt of the diester is also included. Here, examples of the diester of glycerophosphate include saturated fatty acid esters of glycerophosphate or glycerophosphates containing fatty acids selected from higher unsaturated fatty acids, unsaturated fatty acids and saturated fatty acids.

In the present invention, the salt of xanthophyll is not particularly limited as long as it is a physiologically or pharmaceutically acceptable salt. For example, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid; acetic acid, fumaric acid, maleic acid, succinic acid, citric acid, tartrate acid, adipic acid, gluconic acid, Glucoheptoic acid, glucuronic acid, terephthalic acid, methanesulfonic acid, lactic acid, horse uric acid, 1,2-ethandisulfonic acid, isetionic acid, lactobionic acid, oleic acid, pamoic acid, polygalacturonic acid, stearic acid, tannic acid, trifluoromethane Salts with organic acids such as sulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, lauryl ester sulfate, methyl sulfate, naphthalenesulfonic acid, sulfosalicylic acid; quaternary ammonium salt with methyl bromide, methyl iodide, etc .; bromine Salts with halogen ions such as ions, chlorine ions and iodine ions; Salts with alkali metals such as lithium, sodium and potassium; Salts with alkaline earth metals such as calcium and magnesium; Metal salts with iron, zinc and the like; Salt with ammonia; triethylenediamine, 2-aminoethanol, 2,2-iminobis (ethanol), 1-deoxy-1- (methylamino) -2-D-sorbitol, 2-amino-2- (hydroxymethyl)- Examples thereof include salts with organic amines such as 1,3-propanediol, prokine, N, N-bis (phenylmethyl) -1,2-ethanediamine and the like.

In the present invention, the lower limit of xanthophile or a salt thereof is, for example, 0.1% by weight, preferably 0.5% by weight, more preferably 1% by weight, still more preferably, based on the total weight of the composition of the present invention. Is 1.5% by weight, particularly preferably 2% by weight. The upper limit thereof is, for example, 90% by weight, preferably 80% by weight, more preferably 70% by weight, still more preferably 60% by weight, and particularly preferably 50% by weight. Further, the upper limit and the lower limit thereof can be used in combination as appropriate. More specifically, for example, 0.1 to 90% by weight, preferably 0.5 to 80% by weight, more preferably 1 to 70% by weight, still more preferably 1.5 to 60% by weight, and particularly preferably 2 to 2 to 70% by weight. It can be used at 50% by weight.

In the present invention, the Trapa plant is not particularly limited. Specific examples of Trapa plants include Trapa acolnis Nakano, Trapa incisa Sieb. Et Zuc., Trapa japonica Flerov, Trapa trapa, Trapa trapa, Trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trapa trap. L.), trapa natans L. var. Japanica Nakai and the like, preferably trapa natans (Trapa japonica Flerov), trapa (Trapa bispinosa Roxb a. ), And particularly preferably, Trapa bispinosa Roxb.

In the present invention, the processed product of the Trapa japonica can be prepared and produced from the whole or each part of the Trapa japonica. Examples of each part include flowers, spikes, pericarp, fruits, flesh, stems, leaves, branches, branches and leaves, trunks, bark, rhizomes, roots, roots, seeds, insects, heartwood, above-ground parts, or underground parts. The peel is particularly preferable. The method for preparing and producing a processed product of Trapa japonica is not particularly limited, and for example, it can be prepared and produced by a commonly used method.

In the present invention, the lower limit of the content of polyphenol with respect to the total weight of the processed product of Trapa japonica is, for example, 0.1% by weight, preferably 5% by weight, and particularly preferably 10% by weight. The upper limit thereof is, for example, 80% by weight, preferably 70% by weight, and particularly preferably 60% by weight. Further, the upper limit and the lower limit thereof can be used in combination as appropriate. More specifically, the content of polyphenol with respect to the total weight of the processed product of the genus Trapa is, for example, 0.1 to 80% by weight, preferably 5 to 70% by weight, and particularly preferably 10 to 60% by weight. Further, the polyphenol content can be measured by, for example, the FOLIN-CIOCALTEU method or the like.

In the present invention, the processed product of the Trapa japonica plant is, for example, a crushed product of the Trapa japonica plant, an extract thereof, and a dried product thereof. The crushed material, the extract and the dried product of the Trapa genus plant are, for example, the roots, stems, leaves, flower buds, flowers, bark, fruits (seed), fruit bark, etc. of the Trapa genus plant as they are or of appropriate size. It can be prepared and manufactured by cutting, crushing, squeezing, solvent extraction, etc., and in some cases, drying them. Further, it is also possible to prepare and produce by mixing each part of one or more kinds of Trapa japonica plants.

In the present invention, for example, water, an organic solvent, or a mixed solvent thereof can be used as the extraction solvent for the preparation and production of the extract of Trapa japonica. Examples of the organic solvent include lower alcohols such as methanol and ethanol, chloroform, ethyl acetate, n-hexane and the like, and preferred examples include methanol and ethanol. Further, two or more of these organic solvents can be mixed and used.

In the present invention, the amount of the extraction solvent used can be appropriately selected depending on the type and site of the Trapa japonica plant, the type of the extraction solvent, and the like. The weight ratio of the Trapa japonica plant to the extraction solvent is, for example, 1: 2 to 1:30, preferably 1: 3 to 1:20, and particularly preferably 1: 5 to 1:10. The extraction time is, for example, several minutes to 30 days, preferably 1 hour to 15 days. The extraction temperature is, for example, 5 to 100 ° C. The extraction method is not particularly limited, and any method such as batch extraction and continuous extraction using column extraction can be applied.

In the present invention, the obtained extract of Trapa japonica can be used as it is. Further, if necessary, further purification treatment can be added. This purification treatment may be carried out by an ordinary method, and for example, an extract of a Trapa japonica plant can be purified by filtering it by a conventional method. Then, the obtained filtrate can be concentrated under reduced pressure, freeze-dried, or the like to obtain an extract of the Trapa japonica plant according to the present invention.

In the present invention, as a processed product of Trapa japonica, for example, an extract of the pericarp of Trapa japonica or a dried product thereof can be used. The extract of the skin of a trapa japonica or a dried product thereof is obtained by, for example, extracting the skin of a trapa japonica with water or a lower alcohol such as tanol or ethanol, filtering and concentrating it, and optionally adding an excipient or the like. It can be prepared and manufactured by drying.

In the present invention, a particularly preferable processed product of the genus Trapa is a trapa japonica extract, which is a processed product of Trapa japonica.

In the present invention, the lower limit of the content of polyphenol with respect to the total weight of the extract of the pericarp of Trapa japonica is, for example, 0.1% by weight, preferably 1% by weight, more preferably 5% by weight, still more preferably 10% by weight. In particular, it is 20% by weight. The upper limit thereof is, for example, 90% by weight, preferably 80% by weight, more preferably 70% by weight, still more preferably 65% by weight, and particularly preferably 60% by weight. Further, the upper limit and the lower limit thereof can be used in combination as appropriate. More specifically, the content of polyphenols based on the total weight of the extract of the skin of the Trapa japonica is, for example, 0.1 to 90% by weight, preferably 1 to 80% by weight, more preferably 5 to 70% by weight, and further. It is preferably 10 to 65% by weight, and particularly preferably 20 to 60% by weight.

In the present invention, examples of the excipient added to the processed product of the genus Hishi include dextrin, cyclodextrin, lactose, crystalline cellulose, silicon dioxide, cyclic oligosaccharide and the like, and cyclodextrin and cyclic oligosaccharide are preferable. Cyclorodextrin is particularly preferred.

In the present invention, the lower limit of the processed product of the genus Hishi is, for example, 0.1% by weight, preferably 1% by weight, more preferably 10% by weight, still more preferably, with respect to the total weight of the composition of the present invention. Is 25% by weight, particularly 60% by weight, and the upper limit thereof is, for example, 99% by weight, preferably 95% by weight, more preferably 90% by weight, still more preferably 85% by weight, and particularly preferably 80% by weight. Further, the upper limit and the lower limit thereof can be used in combination as appropriate.
More specifically, for example, 0.1 to 99% by weight, preferably 1 to 95% by weight, more preferably 10 to 90% by weight, still more preferably 25 to 85% by weight, and particularly preferably 60 to 80% by weight. Can be used.

In the present invention, other active ingredients (for example, substances having an auxiliary effect) can be further added in addition to xanthophylls or salts thereof and / or processed products of Trapa japonica. For example, Vitamin A; Carotenoids (excluding xanthophile); Vitamin B; Vitamin C; Vitamin D, Vitamin E; Tocotrienol; Glutathion and its derivatives and salts thereof; Catechin, anthocyanin, tannin, rutin, Polyphenols such as isoflavone, chlorogenic acid, ellagic acid, curcumin, coumarin; linoleic acid, α- or γ-linolenic acid, arachidonic acid, eicosapentaenoic acid, sardine acid, docosahexaenoic acid and its derivatives and salts thereof; collagen, elastin , Fibronectin, proteins selected from keratin and their derivatives and hydrolyzates; α-hydroxy acids such as glycolic acid, lactic acid, malic acid, citric acid, salicylic acid and their derivatives and their salts; serum deproteinized, spleen, Placenta, chicken crown, royal jelly, yeast, lactic acid bacteria, bifizus, reishi, carrot, senburi, rosemary, aubergine, garlic, hinokithiol, cepharanthin, aloe, salvia, arnica, chamomile, white birch, otogirisou, eucalyptus, mukuroji, sempukuka , Sanpens, Souhakuhi, Touki, Ibukitranoo, Clara, Sanzashi, Shirayuri, Hop, Neubara, Yokuinin, Dokudami, Seaweed, Natto, Lemongrass, Hibiscus, Ginkgo biloba extract, Phosphatidylserine and other natural products and their extracts; Adenylic acid derivatives such as triphosphate, adenosine diphosphate, adenosine monophosphate; minerals such as iron, vanadium, molybdenum, manganese, copper, potassium, magnesium, calcium, zinc, selenium, iodine; mannitol, xylitol, glucosamine Monosaccharides such as: hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratane sulfate, glycogen, chitin, chitosan and other polysaccharides; deoxyribonucleic acid, ribonucleic acid and other nucleic acids; other glycyrrhizinic acid, guanine, mutin , Ubiquinone, α-lipoic acid, octacosanol, alicin, aliine and the like, and a mixture thereof can be selected from one or more. Preferred are vitamin A; carotenoids (excluding xanthophile); vitamin B; vitamin C; vitamin D, vitamin E; tocotrienol; glutathione and derivatives thereof and salts thereof; catechin, anthocyanin, ellagic acid and the like. Polyphenols; linoleic acid, α- or γ-linolenic acid, arachidonic acid, eikosapentaenoic acid, sardine acid, docosahexaenoic acid and their salts; proteins selected from collagen, elastin, fibronectin, keratin and their derivatives and One or more can be selected from the group consisting of hydrolysates; minerals such as copper and zinc; mutin, ubiquinone, α-lipoic acid and the like, and mixtures thereof. More preferably, vitamin A; carotenoids (excluding xanthophylls); vitamin C; vitamin E; tocotrienols; glutathione and derivatives thereof and salts thereof; polyphenols such as catechin, anthocyanin, ellagic acid; , Docosahexaenoic acid and its derivatives and salts thereof; minerals such as copper and zinc; mutin, ubiquinone, α-lipoic acid and the like, and a mixture thereof can be selected from one or more.

In the present invention, the lower limit of the other active ingredient is, for example, 0.1% by weight, preferably 1% by weight, more preferably 5% by weight, still more preferably 10% by weight, based on the total weight of the composition. %, Especially 20% by weight, and the upper limit thereof is, for example, 99% by weight, preferably 90% by weight, more preferably 80% by weight, still more preferably 70% by weight, and particularly preferably 60% by weight. Further, the upper limit and the lower limit thereof can be used in combination as appropriate.
More specifically, for example, 0.1 to 99% by weight, preferably 1 to 90% by weight, more preferably 5 to 80% by weight, still more preferably 10 to 70% by weight, and particularly preferably 20 to 60% by weight. It is compounded and can be used in combination of one or more.

In the present invention, the composition of the present invention can be used as foods and drinks, foods with functional claims, specified health foods, quasi-drugs, pharmaceuticals (including pharmaceuticals for mammals other than humans), etc., and can be used normally. The active ingredient and the additive to be used can be appropriately blended, and can be appropriately formulated by the formulation method usually used for the product.

In the present invention, foods and drinks for which improvement / prevention of symptoms is permitted are foods having medicinal effects permitted / designated by the national government or public organizations, and are, for example, foods with functional claims and specified health foods. Foods with health claims, special purpose foods, etc. The names and regulations may change depending on the situation, the times, and the systems of each country, but those that are essentially the same are included in the present invention.

In the present invention, the blending amount of the composition of the present invention in foods and drinks, foods with functional claims, foods with specified health claims, quasi-drugs, pharmaceuticals, etc. is not particularly limited, and the object of application (target diseases and symptoms). Type, etc.), application target (humans, animals other than humans (preferably mammals, particularly preferably pets such as dogs and cats)), application target parts, gender and age of application targets, foods and drinks, foods with functional claims , Specified health foods, quasi-drugs, pharmaceuticals, etc., and their administration or ingestion method, frequency, preference, etc. are appropriately set.

In the present invention, the blending amount of the composition of the present invention in foods and drinks, foods with functional claims, specified health foods, quasi-drugs, pharmaceuticals and the like is not particularly limited, but the composition of the present invention per adult per day. The lower limit of the amount is 0.1 mg, preferably 1 mg, more preferably 10 mg, still more preferably 30 mg, particularly preferably 50 mg, and the upper limit thereof is 2000 mg, preferably 1500 mg, more preferably 1000 mg, still more preferably. It is 500 mg, particularly preferably 300 mg. Further, the upper limit and the lower limit thereof can be used in combination as appropriate.
More specifically, for example, it is 0.1 to 2000 mg, preferably 1 to 1500 mg, more preferably 10 to 1000 mg, still more preferably 30 to 500 mg, and particularly preferably 50 to 300 mg.

In the present invention, when the composition of the present invention is used, the lower limit of the daily application amount of xanthophyll or a salt thereof is 0.1 mg, preferably 0.5 mg, more preferably 1 mg, still more preferably. It is 3 mg, particularly preferably 5 mg, the upper limit thereof being 500 mg, preferably 250 mg, more preferably 100 mg, still more preferably 75 mg, and particularly preferably 50 mg. Further, the upper limit and the lower limit thereof can be used in combination as appropriate.
More specifically, for example, it is 0.1 to 500 mg, preferably 0.5 to 250 mg, more preferably 1 to 100 mg, still more preferably 3 to 75 mg, and particularly preferably 5 to 50 mg.

In the present invention, when the composition of the present invention is used, the lower limit of the applied amount of the processed material of Trapa japonica per adult is 0.1 mg, preferably 1 mg, more preferably 10 mg, still more preferably. It is 25 mg, particularly preferably 50 mg, the upper limit thereof being 2000 mg, preferably 1500 mg, more preferably 1000 mg, still more preferably 500 mg, and particularly preferably 300 mg. Further, the upper limit and the lower limit thereof can be used in combination as appropriate.
More specifically, for example, it is 0.1 to 2000 mg, preferably 1 to 1500 mg, more preferably 10 to 1000 mg, still more preferably 25 to 500 mg, and particularly preferably 50 to 300 mg.

One aspect of the present invention is an oral or parenteral composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa. The composition of the present invention can be used as an oral composition and a parenteral composition.

One aspect of the present invention is a food or drink or pharmaceutical composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa. The composition of the present invention can be used as a food or drink and a medicine.

One aspect of the present invention is a composition for supplements containing xanthophylls or salts thereof and processed products of Trapa japonica. The composition of the present invention can be used as a supplement.

One aspect of the present invention is an ophthalmic composition containing xanthophile or a salt thereof and a processed product of the genus Trapa, preferably all other ophthalmic compositions except for diabetic retinopathy. Is all other ophthalmic compositions except for diabetic retinopathy and cataracts.

In the present invention, the composition of the present invention is, in addition to xanthophile or a salt thereof and / or a processed product of a plant belonging to the genus Hishi, if necessary, other components such as excipients, thickeners, emulsifiers (eg, for example). Beeswax, glycerin fatty acid ester) and the like can be mixed to prepare a desired form. The form of the composition of the present invention is not particularly limited, and examples thereof include supplements such as soft capsules, hard capsules, liquids, jellies, gummies, tablets, powders, and gels.

In the present invention, when prepared as a composition for foods and drinks of the present invention, in addition to xanthophile or a salt thereof and / or a processed product of a Trapa genus plant, other components such as a sweetener and a coloring agent are required. , Preservatives, thickeners, stabilizers, gelling agents, glues, antioxidants, color formers, bleaching agents, fungicides (antifungal agents), yeast foods, gum bases, flavors, acidulants, seasonings, It can be prepared into a desired form by mixing an emulsifier, a pH adjuster, a fungicide, a swelling agent, a nutritional enhancer, other food and drink materials, and the like. For example, the form thereof is not particularly limited, and supplement-type foods such as gelled agents, granules, fine granules, capsules, soft capsules, tablets, powders, liquids, and semi-solid agents; carbonated beverages, refreshing beverages, etc. Beverages such as dairy beverages, alcoholic beverages, fruit juice beverages, teas, nutritional beverages; powdered beverages such as powdered juices and powdered soups; It can be in the form of noodles, cereals, jams, seasonings, etc. These forms can be used, for example, as foods and drinks for preventing and / or improving visual function deterioration, for example, in addition to general foods and drinks, dietary supplements, foods with functional claims, foods for specified health use. It can also be used as a nutritive for foods for the sick.

In the present invention, when prepared as a pharmaceutical composition (pharmaceutical product, quasi-drug, etc.) of the present invention, in addition to xanthophyll or a salt thereof and / or a processed product of Trapa japonica, other medicinal effects as necessary. Ingredients, pharmaceutically acceptable carriers, additives and the like can be blended. For example, as a pharmaceutically acceptable carrier and additive, a binder, a disintegrant, a lubricant, a wetting agent, a buffering agent, a preservative, a fragrance and the like can be mixed to prepare a desired form. can.
For example, the form thereof is not particularly limited, and injections, external preparations, inhalants, suppositories, films, troches, liquids, powders, tablets, granules, capsules, syrups, eye drops. , Eye drops, nasal drops, etc. Among these forms, a form suitable for oral administration (that is, an oral drug) is preferable, and for example, troches, liquids, powders, tablets, granules, capsules, soft capsules, syrups and the like are particularly preferable. These forms can be used, for example, as pharmaceuticals for the prevention and / or treatment of visual deterioration.

One aspect of the present invention is an ophthalmic composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa. The ophthalmic composition of the present invention can be used for various eye-related symptoms, for example, under the guidance and management of a doctor or pharmacist, or under the appropriate health care of an individual.

One aspect of the present invention is a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica for the prevention and / or improvement of visual dysfunction and associated subjective symptoms. The composition of the present invention can be used for prevention and / or improvement of visual deterioration.

In the present invention, "decreased visual function" means that the ability to perceive visual information such as characters and images, that is, visual information such as morphology, color, lightness and darkness, and movement of an object is reduced, and for example, eye fatigue. , Eye aging, or deterioration of eye focus adjustment function (the ability to change the thickness of the crystalline body and adjust focus to the retina due to contraction and relaxation of hairy muscles, etc.); Deterioration of visual acuity due to age; including deterioration of visual acuity associated with diseases such as tired eyes, cataracts, and diabetic retinopathy. Further, "prevention and / or improvement of visual function deterioration" means prevention or suppression, treatment or improvement of the above-mentioned visual function deterioration, and includes maintenance of visual function. Decreased visual function is induced, for example, by aging, UV light, poor circulation, dryness, and / or reactive oxygen species. Further, the "subsequent subjective symptom" is not particularly limited as long as it is a subjective symptom due to a decrease in visual function, and examples thereof include shoulder, nape, back or waist stiffness.

In the present invention, for a product related to the composition of the present invention, packaging of the product, information related to the product, or an advertisement related to the product (for example, transaction documents, instruction manuals, attachments, mail order catalogs, Internet sites, etc.). Can be labeled as "prevention (or suppression) and / or improvement (or treatment) of visual deterioration", and "prevention and / or improvement of visual deterioration" is induced by, for example, ultraviolet rays. Suppression of eye disorders, increase in the amount of pigment in the yellow spots of the eyes, which decreases with age, protection from light stimuli such as blue light, improvement of (decreased) contrast sensitivity, conditioning of the eyes, eyes Relieves fatigue, reduces eye fatigue (due to VDT work, etc.), increases the amount of pigment in the center of the retina, protects the eyes from light stimuli (received in daily life), maintains eye health, (normal) Maintains focus adjustment function, relieves eye fatigue, relieves dry eyes, relieves deterioration of focus adjustment function, maintains visual function, maintains health of yellow spots of eyes, supports focus adjustment function , Supports contrast sensitivity (power to discriminate color depth), maintains viewing power, helps focus adjustment function at hand, relieves the burden on the shoulders and neck muscles due to the use of eyes, etc. It is also possible to display similar to them.

One aspect of the present invention is a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica for the prevention and / or treatment of eye diseases. The compositions of the present invention can be used for the prevention and / or treatment of eye diseases.

In the present invention, the eye disease is, for example, a disease induced by aging, ultraviolet rays, poor blood circulation, dryness, active oxygen and / or inflammation, and specifically, presbyopia, cataract, age-related macular degeneration, and the like. Examples thereof include diabetic retinopathy, retinal pigment degeneration, central serous chorioretinosis, cataract, cataract, presbyopia, myopia, dry eye, winglet, inflammatory eye disease, and the like, preferably eye fatigue. Cataract, age-related macular degeneration, diabetic retinopathy, presbyopia, myopia, dry eye, and particularly preferably presbyopia.

In the present invention, the corneal disorder is not particularly limited as long as it is corneal epithelial cell death and eye diseases caused by it (dry eye, inflammatory eye disease, etc.). Preferably, it is UV-induced corneal damage, UV-induced corneal epithelial cell death and the resulting eye disease.

In the present invention, lens degeneration is a state in which a protein present in the lens is denatured, and the cause thereof is not particularly limited. A state in which the crystalline lens is turbid (white turbid), hardened, colored (yellowed) or changed in shape is preferable, and a state in which the crystalline lens is turbid (white turbid) or hardened is particularly preferable.

In the present invention, the eye accommodation function is not particularly limited as long as it is a function of adjusting the visual function. The focus adjustment function is preferable, and the focus adjustment function in the crystalline lens is particularly preferable.

In the present invention, the retinal choroidal disorder is an eye disease caused by damage to the retina and the damage thereof, and preferably a damage to the retina and a grape membrane disease caused by the damage (a disease such as the retina, choroid, sclera, etc.). Is.

In the present invention, "characterized by combining xanthophile or a salt thereof with a processed product of Trapa japonica" may mean that xanthophile or a salt thereof and a processed product of Trapa japonica may be used in combination as a single agent. It means that it may be used as a compounding agent for each component. More preferably, it is used as a compounding agent.

In the present invention, "prevention" means prevention of the onset and / or progression of each symptom or disease.

In the present invention, "treatment" means treatment of each symptom or disease.

In the present invention, "improvement" means improvement of each symptom or disease.

In the present invention, "containing" means "substantially containing only", "containing only", "containing as an active ingredient", and "substantially containing only" as an active ingredient. It is also the scope of the present invention to read "contains as" and "contains only ... as an active ingredient".

One aspect of the invention is a combination of xanthophylls or salts thereof and processed Trapa japonica for use in the prevention or amelioration of eye symptoms and / or findings. For each definition of the embodiment, each definition of a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica can be applied mutatis mutandis.

One aspect of the present invention is the use of a composition containing xanthophylls or salts thereof and processed products of Trapa japonica in the manufacture of foods and drinks or pharmaceuticals for the prevention or amelioration of eye symptoms and / or findings. For each definition of the embodiment, each definition of a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica can be applied mutatis mutandis.

One aspect of the present invention is use in the prevention or amelioration of ocular symptoms and / or findings of compositions containing xanthophylls or salts thereof and processed products of Trapa japonica. For each definition of the embodiment, each definition of a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica can be applied mutatis mutandis.

One aspect of the invention is a method for use in the prevention or amelioration of eye symptoms and / or findings, comprising administering an effective amount of a composition containing xanthophyll or a salt thereof and a processed product of a family plant. Is. In one aspect of the present invention, an effective amount of xanthophyll or a salt thereof and a processed product of Trapa japonica can be administered simultaneously or sequentially, and other components may be administered simultaneously or sequentially as needed. can. For each definition of the embodiment, each definition of a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica can be applied mutatis mutandis.

Another aspect of the present invention is an ophthalmic composition containing a processed product of the genus Trapa, and its use. For each definition of the embodiment, each definition of a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica can be applied mutatis mutandis.

Another aspect of the present invention is a novel use of a corneal epithelial cell death inhibitor containing lutein or a salt thereof and an ophthalmic composition containing lutein or a salt thereof. For each definition of the embodiment, each definition of a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica can be applied mutatis mutandis.

Examples of pharmacological tests are shown below, but these examples are for better understanding of the present invention and do not limit the scope of the present invention.

[Pharmacology test 1-1]
It was evaluated whether or not the decrease in the number of living cells due to the irradiation with ultraviolet rays was suppressed when the corneal epithelial cells were treated with the composition of the present invention before the irradiation with ultraviolet rays (UV-B).

(Test method)
SV40 immortalized human corneal epithelial cells (HCE-T: Institute of Physical and Chemical Research, Bioresource Center, Cell No .: RCB2280) were seeded in 96-well plates (1 × 10 ⁴ cells / well), and SHEM medium (15% Fetal Bovine Serum) was inoculated. 5 μg / mL Insulin, 10 ng / mL Human Epidermal Growth Factor, 40 μg / mL Gentamicin-containing DMEM / F-12 medium) was cultured for 1 day.
The next day, the SHEM medium was removed, and SV40 immortalized human corneal epithelial cells were washed with PBS (Phosphate Buffered Saline).
PBS containing 0.01% (w / v) Hishi extract, PBS containing 100 μM lutein, PBS containing 0.01% (w / v) Hishi extract and 100 μM lutein, or PBS containing no test substance (control) Exchanged for.
Then, the corneal epithelial cells were irradiated with 120 mJ / cm ² UV-B (irradiation intensity: about 1 mW / cm ² , irradiation time: about 120 seconds).
After exchanging the medium of each group with DMEM / F-12 medium, culturing at 37 ° C. until the next day, using CellTiter96 (registered trademark) Aqueous One Solution Cell Proflation Association (Promega, Catalog No .: G3580). The number of living cells was measured, and the cell viability was calculated according to the following formula 1.
The Hishi extract and lutein used in this test were purchased from Hayashikane Sangyo Co., Ltd. and ChromaDex Co., Ltd., respectively.

[Equation 1]
Cell viability (%) = (number of viable cells in each group / number of viable cells in UV-B non-irradiated control group) x 100

(result)
The test results are shown in FIG. In FIG. 1, the values indicate the average value ± the standard error (N = 3).

(Discussion)
As is clear from FIG. 1, when the corneal epithelial cells were treated with Hishi extract alone, Lutein alone or Hishi extract + lutein prior to UV-B irradiation, the cell viability was improved with respect to the control. That is, effective treatment of trapa japonica processed products alone, xanthophylls alone, and trapa japonica processed products in combination with xanthophylls effectively causes corneal epithelial cell death induced by UV irradiation. It was shown that it can be suppressed. In particular, when a processed product of Trapa japonica and xanthophyll were used in combination, both were shown to act synergistically or complementarily to effectively suppress corneal epithelial cell death induced by UV irradiation.

[Pharmacology test 1-2]
It was evaluated whether or not the decrease in the number of living cells due to the irradiation with ultraviolet rays was suppressed when the corneal epithelial cells were treated with the composition of the present invention before the irradiation with ultraviolet rays (UV-B).

(Test method)
SV40 immortalized human corneal epithelial cells (HCE-T: Institute of Physical and Chemical Research, Bioresource Center, Cell No .: RCB2280) were seeded in 96-well plates (1 × 104 cells / well), and SHEM medium (15% Fetal Bovine Serum, 5 μg / mL Insulin, 10 ng / mL Human Epithelium Growth Factor, 40 μg / mL Gentamicin-containing DMEM / F-12 medium) was cultured for 1 day.
The next day, the SHEM medium was removed, and SV40 immortalized human corneal epithelial cells were washed with PBS (Phosphate Buffered Saline).
PBS containing 0.01% (w / v) Hishi extract, PBS containing 100 μM astaxanthin, PBS containing 0.01% (w / v) Hishi extract and 100 μM astaxanthin, or PBS containing no test substance (control) Exchanged for.
Then, the corneal epithelial cells were irradiated with 120 mJ / cm2 UV-B (irradiation intensity: 1.1 mW / cm2, irradiation time: 109 seconds).
After exchanging the medium of each group with DMEM / F-12 medium, culturing at 37 ° C. until the next day, using CellTiter96 (registered trademark) Aquieus One Solution Cell proliferation Assay (manufactured by Promega, catalog number: G3580). The number of living cells was measured, and the cell viability was calculated according to the following formula 1. The hissi extract and astaxanthin used in this test were purchased from Hayashikane Sangyo Co., Ltd. and Tronto Research Chemicals, respectively.

[Equation 1]
Cell viability (%) = (number of viable cells in each group / number of viable cells in UV-B non-irradiated control group) x 100

(result)
The test results are shown in FIG. In FIG. 4, the values indicate the average value ± the standard error (N = 3).

(Discussion)
As is clear from FIG. 4, when the corneal epithelial cells were treated with Hishi extract alone, Astaxanthin alone or Hishi extract + Astaxanthin before UV-B irradiation, the cell viability was improved with respect to the control. That is, effective treatment of trapa japonica processed products alone, xanthophylls alone, and trapa japonica processed products in combination with xanthophylls effectively causes corneal epithelial cell death induced by UV irradiation. It was shown that it can be suppressed.
In particular, when a processed product of Trapa japonica and xanthophyll were used in combination, it was shown that both act synergistically and can effectively suppress corneal epithelial cell death induced by ultraviolet irradiation.

[Pharmacology test 2]
It was evaluated whether or not the white turbidity (opacity) of the crystalline lens and the damage of the retina were improved when the diabetic model rat was treated with the composition of the present invention.

1. 1. Test animal (use animal)
Wistar male rats (7 weeks old, Japan Charles River Co., Ltd. Hino Breeding Center) were brought into the breeding room of Ina Research Research Center Co., Ltd. After quarantine including acclimation for 6 days, it was used for the experiment.
During the test period, the animals were bred in the same laboratory controlled at a temperature of 23 ± 2 ° C., a humidity of 55 ± 15%, and a light-dark cycle of 12 hours (light period: 7:00 am to dark period: 7:00 pm). Solid feed (CRF-1, Oriental Yeast Co., Ltd., Chiba) and drinking water were allowed to be freely ingested.

2. 2. Preparation of diabetic model rats Streptozotocin (STZ) was prepared at 45 mg / mL with physiological saline as the first dose, and 1 mL / kg was administered once intravenously, and 7 days later, STZ was administered with physiological saline at 25 mg / mL. A single intravenous dose of 1 mL / kg was administered as a second dose to induce type 1 diabetes. The same amount of physiological saline was administered to the control group (normal group). Those having a satiety blood glucose level of 250 mg / dL or more (diabetes group: DM) on the 6th day after the second STZ administration were used for the subsequent experiments.

3. 3. Experimental protocol The above DM rats were assigned to the following 4 groups on the 6th day after the second STZ administration so that the blood glucose levels were even.
Normal group: Water for injection 2 mL / kg / day (n = 8)
Control group: DM + water for injection 2 mL / kg / day (n = 8)
Hishi extract group: DM + 66% Hishi extract content 2 mg / kg / day (n = 8)
Lutein group: DM + lutein 20% content 2 mg / kg / day (n = 8)
Hishi extract + lutein group: DM + 66% lutein content 2 mg / kg / day + lutein 20% content 2 mg / kg / day (n = 8)
The subject administration was started the day after the allocation, and the change over time was observed for 69 days. Hishi extract is diluted with water for injection to a concentration of 1 mg / mL and 2 mL / kg / day, and lutein is diluted with safflower oil to a concentration of 1 mg / mL and 2 mL / kg / day is diluted with a polypropylene injection tube and an oral sonde for rats. Was administered orally once daily.
The white turbidity (turbidity) of the crystalline lens was evaluated on the 70th day from the start date of administration to evaluate the white turbidity (turbidity). The electroretinogram was measured 2 days before the start of administration of the subject and 43 days after the start of administration, a total of 2 times.
The hissi extract and lutein used in this test were purchased from Hayashikane Sangyo Co., Ltd. and Katra Phytochem [India] Private Limited, respectively.

4. Effect on lens white turbidity (opacity) The presence or absence of the lens cloudiness (opacity) inhibitory effect of Hishi extract, lutein and Hishi extract + lutein was examined using diabetic model rats.
Streptozotocin was administered to Wistar rats (male, 8 weeks old) for the first time (45 mg / kg, iv) and 7 days later for the second time (25 mg / kg, iv) to induce type 1 diabetes. I let you. The Hishi extract group contains 66% Hishi extract (2 mg / kg), the lutein group contains 20% lutein (2 mg / kg), and the Hishi extract + lutein group contains 66% Hishi extract (2 mg / kg) and 20% lutein (2 mg / kg). 2 mg / kg) was orally administered once a day.
The crystalline lens was collected on the 70th day after the end of the 69-day administration period, and the ratio of the number of completely cloudy (opaque) crystalline lenses (incidence rate of complete cloudiness) was evaluated.
The Hishi extract and lutein used in this test were purchased from Hayashikane Sangyo Co., Ltd. and Katra Phytochem [India] Private Limited, respectively.

[Equation 2]
Complete cloudiness rate (%) = (number of eyes completely clouded in each group / total number of eyes in each group) x 100

(result)
The test results are shown in FIG.

(Discussion)
As is clear from FIG. 2, all of the cases of administration of Hishi extract alone, lutein alone, and Hishi extract + lutein suppressed the cloudiness (opacity) of the crystalline lens as compared with the control. That is, it was shown that the white turbidity (turbidity) of the crystalline lens was suppressed in both the case where the processed product of the genus Trapa was used alone, the xanthophyll was used alone, and the processed product of the genus Trapa and the xanthophyll were used in combination. ..

5. Effect on retinal damage The presence or absence of the inhibitory effect of Hishi extract, lutein and Hishi extract + lutein on retinal damage was examined using diabetic model rats.
Streptozotocin was administered to Wistar rats (male, 8 weeks old) for the first time (45 mg / kg, iv) and 7 days later for the second time (25 mg / kg, iv) to induce type 1 diabetes. I let you. The Hishi extract group contains 66% Hishi extract (2 mg / kg), the lutein group contains 20% lutein (2 mg / kg), and the Hishi extract + lutein group contains 66% Hishi extract (2 mg / kg) and 20% lutein (2 mg / kg). 2 mg / kg) was orally administered once a day.
Using the data collection / analysis system PowerLab (PowerLab system), electroretinograms (wave a and wave b) were measured and evaluated 2 days before the start of administration of the subject and 43 days after the start of administration.
The Hishi extract and lutein used in this test were purchased from Hayashikane Sangyo Co., Ltd. and Katra Phytochem [India] Private Limited, respectively.
Here, the electroretinogram is a potential change recorded when the retina is irradiated with light, and is used when the retinal function is electrophysiologically evaluated.
The basic form of this electroretinogram is classified into the first non-potential fluctuation (a wave) caused by light irradiation, and then the large positive potential fluctuation (b wave) that rises sharply and then drops sharply. The hyperpolarized phase derived from photoreceptor cells and the b-wave amplitude indicate the depolarized layer derived from Muller cells and are used to grasp the state of retinal function. That is, if any damage occurs to the retina due to various diseases or the like, the amplitude of each wave on the electroretinogram decreases.

[Equation 3]
Amplitude change rate (%) = (potential fluctuation range on the 43rd day of each group / potential fluctuation range 2 days before the start of administration) × 100

(result)
The test results are shown in FIG.

(Discussion)
As is clear from FIG. 3, all of the administrations of Hishi extract alone, Lutein alone and Hishi extract + lutein suppressed or improved the decrease in the amplitudes of the a wave and the b wave as compared with the control. That is, it was shown that there is a possibility of suppressing or ameliorating retinal damage when the processed product of Trapa japonica is used alone, xanthophyll alone, or the processed product of Trapa japonica and xanthophyll are used in combination. ..
[Example of pharmaceutical product]
Examples of the formulations are shown below, but these examples are for better understanding of the present invention and do not limit the scope of the present invention, and the present invention is limited to these examples of formulations only. It's not something.

The blending amount of each component in the pharmaceutical product example is the content per capsule in the case of soft capsules.

Pharmaceutical example 1
Hishi extract 33mg
Appropriate amount of glycerin fatty acid ester

Pharmaceutical example 2
Lutein 7.5mg
Hishi extract 33mg
Appropriate amount of glycerin fatty acid ester

Pharmaceutical example 3
Lutein 7.5mg
Hishi extract 33mg
Vitamin E 75mg
Appropriate amount of glycerin fatty acid ester

Pharmaceutical example 4
Lutein 7.5mg
Hishi extract 33mg
Docosahexaenoic acid 100 mg
Appropriate amount of glycerin fatty acid ester

Pharmaceutical example 5
Hishi extract 33mg
Docosahexaenoic acid 100 mg
Appropriate amount of glycerin fatty acid ester

Pharmaceutical example 6
Lutein 7.5mg
Docosahexaenoic acid 100 mg
Appropriate amount of glycerin fatty acid ester

Pharmaceutical example 7
Astaxanthin 3 mg
Hishi extract 33mg
Vitamin E 75mg
Appropriate amount of glycerin fatty acid ester

In the pharmaceutical examples 1 to 7, a desired pharmaceutical product can be formulated by appropriately adjusting the type and amount of lutein, hissi extract, astaxanthin, and other compounding components.

The composition containing xanthophyll of the present invention or a salt thereof and a processed product of Trapa japonica can be used for prevention and / or improvement of deterioration of visual function.

Claims (49)

A composition containing xanthophyll or a salt thereof and a processed product of the genus Trapa. The composition according to claim 1, wherein the xanthophyll is at least one selected from the group consisting of lutein, astaxanthin, β-cryptoxanthin, zeaxanthin, mesozeaxanthin, canthaxanthin, capsanthin and fucoxanthin. The composition according to claim 1 or 2, wherein the xanthophyll is at least one selected from the group consisting of lutein, astaxanthin, zeaxanthin and mesozeaxanthin. The processed product of the Trapa genus plant is a processed product of at least one Trapa genus plant selected from the group consisting of Trapa incisa, Trapa incisa, Trapa japonica, Trapa japonica, Trapa natans and Water chestnut, according to any one of claims 1 to 3. The composition described. The composition according to any one of claims 1 to 4, wherein the processed product of the genus Trapa is a pulverized product and / or an extract of the peel of the genus Trapa. The composition according to any one of claims 1 to 5, wherein the processed product of the genus Trapa contains 0.1 to 80% by weight of polyphenol with respect to the total weight of the processed product of the genus Trapa. A composition containing lutein or a salt thereof and a processed product of Tobishi. The composition according to claim 7, wherein the processed product of Tobishi is a pulverized product and / or an extract of pericarp of Tobishi. The composition according to claim 7 or 8, wherein the processed Tobishi product contains 0.1 to 80% by weight of polyphenol based on the total weight of the processed Tobishi product. The composition according to any one of claims 1 to 9, wherein the composition is for oral or parenteral use. The composition according to any one of claims 1 to 10, wherein the composition is for food and drink or pharmaceutical use. The composition according to any one of claims 1 to 11, wherein the composition is for a supplement. The composition according to any one of claims 1 to 12, wherein the composition is for ophthalmology. The composition according to any one of claims 1 to 13, wherein the composition is a soft capsule, a hard capsule, a liquid preparation, a jelly, a gummy candy, a tablet or a powder. The composition according to any one of claims 1 to 14, for preventing and / or ameliorating visual dysfunction and associated subjective symptoms. The composition according to claim 15, wherein the deterioration of visual function is eye fatigue, aging of the eye, or deterioration of the accommodation function of the eye. The composition according to claim 15 or 16, wherein the visual dysfunction is a visual dysfunction induced by aging, ultraviolet light, poor circulation, dryness, reactive oxygen species and / or inflammation. The composition according to claim 15, wherein the subjective symptom is stiff shoulders, nape, back or lower back. The composition according to claims 1 to 14, for the prevention and / or treatment of eye diseases. 19. The composition of claim 19, wherein the eye disease is an eye disease induced by aging, ultraviolet light, poor circulation, dryness, reactive oxygen species and / or inflammation. Eye diseases include eye fatigue, cataracts, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, central serous chorioretinopathy, glaucoma, vegetitis, presbyopia, myopia, dry eyes and inflammatory eye diseases. The composition according to claim 19 or 20, which is selected from the group consisting of. The composition according to any one of claims 1 to 14, for the prevention, amelioration and / or treatment of corneal disorders. 22. The composition of claim 22, wherein the corneal disorder is an ultraviolet-induced corneal disorder. The composition according to any one of claims 1 to 14, for the prevention, amelioration and / or treatment of lens degeneration. 24. The composition of claim 24, wherein the lens degeneration is opacity or hardening of the lens. The composition according to any one of claims 1 to 14, for the prevention, improvement and / or treatment of deterioration of accommodation function. The composition according to claim 26, wherein the accommodation function is an accommodation function. The composition according to any one of claims 1 to 14, for the prevention, amelioration and / or treatment of retinochoroidal disorders. 28. The composition of claim 28, wherein the retinal choroidal disorder is damage to the retina. An agent for preventing and / or ameliorating visual dysfunction and associated subjective symptoms, which is characterized by combining xanthophyll or a salt thereof with a processed product of the genus Trapa. A prophylactic and / or therapeutic agent for eye diseases, which comprises a combination of xanthophyll or a salt thereof and a processed product of the genus Trapa. A preventive, ameliorating and / or therapeutic agent for corneal disorders, which comprises combining xanthophyll or a salt thereof with a processed product of the genus Trapa. A prophylactic, ameliorating and / or therapeutic agent for lens degeneration characterized by a combination of xanthophyll or a salt thereof and a processed product of the genus Trapa. A preventive, ameliorating and / or therapeutic agent for the deterioration of accommodation function, which is characterized by combining xanthophyll or a salt thereof with a processed product of the genus Trapa. A preventive, ameliorating and / or therapeutic agent for reticulochoroidal disorders, which comprises a combination of xanthophyll or a salt thereof and a processed product of the genus Trapa. An ophthalmic composition containing a processed product of the genus Trapa. The ophthalmic composition according to claim 36 for preventing and / or ameliorating visual dysfunction and associated subjective symptoms. 36. The ophthalmic composition according to claim 36, for the prevention and / or treatment of eye diseases. 36. The ophthalmic composition of claim 36 for the prevention, amelioration and / or treatment of corneal disorders. 36. The ophthalmic composition of claim 36 for the prevention, amelioration and / or treatment of lens degeneration. 36. The ophthalmic composition of claim 36 for the prevention, amelioration and / or treatment of reticulochoroidal disorders. A composition containing xanthophylls or salts thereof and processed products of Trapa japonica for use in the prevention or amelioration of eye symptoms and / or findings. A composition containing xanthophylls or salts thereof and processed products of Trapa japonica for use in the prevention and / or treatment of eye diseases. Use of compositions containing xanthophylls or salts thereof and processed Trapa japonica in the manufacture of foods and drinks or pharmaceuticals for the prevention or amelioration of eye symptoms and / or findings. Use of compositions containing xanthophylls or salts thereof and processed Trapa japonica in the manufacture of foods and drinks or pharmaceuticals for the prevention and / or treatment of eye diseases. Use for the prevention or amelioration of ocular symptoms and / or findings of compositions containing xanthophylls or salts thereof and processed Trapa japonica. Use in the prevention and / or treatment of eye diseases of compositions containing xanthophylls or salts thereof and processed products of Trapa japonica. A method for use in the prevention or amelioration of eye symptoms and / or findings, comprising administering an effective amount of a composition containing xanthophyll or a salt thereof and a processed Trapa japonica. A method for use in the prevention and / or treatment of eye diseases, comprising administering an effective amount of a composition containing xanthophyll or a salt thereof and a processed product of Trapa japonica.

Images